Gregoire Pave

Gregoire Pave, PhD, is an experienced investment research analyst and director with a robust background in pharmaceuticals and biotechnology. Currently serving as an Investment Research Analyst at Shard Capital and Director at FinBio Consulting since November 2023, Gregoire also provides consulting services for Alpha Blue Ocean, a global alternative investment firm, since April 2020. Previous experience includes serving as an equity research analyst at Hardman & Co, where responsibilities encompassed investment reports, pre-IPO documentation, financial valuations, and client relations. Gregoire's earlier roles in cancer research involved project leadership and management in medicinal chemistry at Cancer Research Technology, along with postdoctoral research at Imperial College London. Education includes a Doctor of Philosophy in Medicinal and Pharmaceutical Chemistry from Université d'Orléans and postdoctoral research in natural product synthesis at Imperial College London.